Ekso GT™ Robotic Exoskeleton Cleared by FDA for Use With Stroke and Spinal Cord Injury Patients
Apr 04, 2016 11:00 am UTC| Business
RICHMOND, Calif., April 04, 2016 -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its...
Apr 04, 2016 11:00 am UTC| Business
Albany, NY, April 04, 2016 -- Bottled water is one of the largest commercially sold beverage categories and fastest selling drinks globally. Growing concerns over the health effects of carbonated beverages and the easy...
Axsome Therapeutics to Present at the 15th Annual Needham Healthcare Conference
Apr 04, 2016 11:00 am UTC| Business
NEW YORK, April 04, 2016 -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced...
Natus Medical Announces Preliminary Revenue for the First Quarter 2016
Apr 04, 2016 11:00 am UTC| Business
PLEASANTON, Calif., April 04, 2016 -- Natus Medical Incorporated (NASDAQ:BABY) today announced preliminary revenue for is first quarter ended March 31, 2016. Revenue for the first quarter of 2016 is expected to be...
Apr 04, 2016 11:00 am UTC| Business
Obtained FDA clearance in November 2015 for Ablatherm Robotic HIFU;Fourth quarter 2015 HIFU Division revenues tripled over fourth quarter 2014;Overall fourth quarter 2015 revenues increased 82% over 2014 to EUR 11.8...
Plug Power to Exhibit and Host Press Conference at MODEX 2016
Apr 04, 2016 11:00 am UTC| Business
LATHAM, N.Y., April 04, 2016 -- Plug Power Inc. (NASDAQ:PLUG), a leader in providing clean, reliable energy solutions, today announced it will exhibit and host a press conference at MODEX 2016, happening now through...
Apr 04, 2016 11:00 am UTC| Business
Positive data from Zilretta Phase 2b and Phase 3 clinical trials demonstrate consistent efficacy across both studies with substantial and persistent pain reliefIn the Phase 3 trial Zilretta, in contrast to...